Use of G-CSF for the Treatment of Unexplained Recurrent Miscarriage

• Status: Completed
• Trial end date: 2007-01-01
• Target enrollment: 0
• Participant gender: Female

Summary

In order to investigate the effectiveness of G-CSF in preventing embryo demise, the investigators administered this cytokine to women with recurrent miscarriage in a randomized controlled study compared to women treated with placebo. Sixty eight women with unexplained primary recurrent miscarriage, all of them with at least four consecutive abortions and negative for all clinical investigations were selected for this study. Patients were randomly treated with G-CSF, starting on the 6th day after ovulation, or with placebo.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Florence
• Treatments: Lenograstim; Pharmaceutical Solutions

Criteria

Inclusion Criteria:

• four or more previous consecutive abortion,

• failed previous treatment with intravenous immunoglobulins

• negative to all clinical investigation for recurrent miscarriage

Exclusion Criteria:

• in the last abortion a fetal karyotype showing chromosomal abnormality

• previous successful pregnancy